DK3213750T3 - Kombination af to antivirale midler til behandling af hepatitis c - Google Patents

Kombination af to antivirale midler til behandling af hepatitis c Download PDF

Info

Publication number
DK3213750T3
DK3213750T3 DK17165207.6T DK17165207T DK3213750T3 DK 3213750 T3 DK3213750 T3 DK 3213750T3 DK 17165207 T DK17165207 T DK 17165207T DK 3213750 T3 DK3213750 T3 DK 3213750T3
Authority
DK
Denmark
Prior art keywords
hepatitis
treatment
combination
antiviral medicines
antiviral
Prior art date
Application number
DK17165207.6T
Other languages
English (en)
Inventor
Sven Mensing
Barry M Bernstein
Sandeep Dutta
Wei Liu
Thomas J Podsadecki
Andrew L Campbell
Rajeev M Menon
Chih-Wei Lin
Tianli Wang
Walid M Awni
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3213750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK3213750T3 publication Critical patent/DK3213750T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17165207.6T 2013-03-14 2014-03-14 Kombination af to antivirale midler til behandling af hepatitis c DK3213750T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783376P 2013-03-14 2013-03-14
EP14719977.2A EP2968301B1 (en) 2013-03-14 2014-03-14 Combination of two antivirals for treating hepatitis c

Publications (1)

Publication Number Publication Date
DK3213750T3 true DK3213750T3 (da) 2020-10-19

Family

ID=50588882

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14719977.2T DK2968301T3 (da) 2013-03-14 2014-03-14 Kombination af to antiviraler til behandling af hepatitis c
DK17165207.6T DK3213750T3 (da) 2013-03-14 2014-03-14 Kombination af to antivirale midler til behandling af hepatitis c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14719977.2T DK2968301T3 (da) 2013-03-14 2014-03-14 Kombination af to antiviraler til behandling af hepatitis c

Country Status (26)

Country Link
US (1) US20140275099A1 (da)
EP (3) EP3213750B1 (da)
JP (4) JP6441303B2 (da)
KR (2) KR20210013344A (da)
CN (2) CN108159393A (da)
AU (2) AU2014239563B2 (da)
BR (1) BR112015023017B1 (da)
CA (1) CA2901810C (da)
CY (2) CY1119025T1 (da)
DK (2) DK2968301T3 (da)
EA (2) EA033257B1 (da)
ES (2) ES2824473T3 (da)
HK (2) HK1244668A1 (da)
HR (2) HRP20171036T1 (da)
HU (2) HUE033010T2 (da)
IL (1) IL240419B (da)
LT (2) LT2968301T (da)
MX (2) MX362616B (da)
NZ (2) NZ631155A (da)
PL (2) PL3213750T3 (da)
PT (2) PT3213750T (da)
RS (2) RS56202B1 (da)
SG (2) SG10201708306WA (da)
SI (2) SI2968301T1 (da)
TW (2) TWI642436B (da)
WO (1) WO2014152514A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
LT2968301T (lt) 2013-03-14 2017-05-25 Abbvie Inc. Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui
MX2015017953A (es) * 2013-07-02 2016-10-28 Abbvie Inc Metodos para tratar el virus de hepatitis c.
JP2016534082A (ja) * 2013-10-25 2016-11-04 アッヴィ・インコーポレイテッド Hcvの治療方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
MX2016012799A (es) * 2014-04-02 2016-12-12 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
MX2016012722A (es) * 2014-04-02 2016-12-16 Abbvie Inc Metodos para tratar el virus de la hepatitis c.
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3313378A1 (en) * 2015-06-26 2018-05-02 AbbVie Inc. Solid pharmaceutical compositions for treating hcv
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Hcvを処置するための方法
AU2016296709C1 (en) * 2015-07-17 2022-02-24 Abbvie Inc. Solid pharmaceutical compositions for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109715161A (zh) * 2016-09-23 2019-05-03 艾伯维公司 剂量调整
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
JP2021521118A (ja) * 2018-04-10 2021-08-26 アテア ファーマシューティカルズ, インコーポレイテッド 肝硬変を伴うhcv感染患者の治療
EP3883569A1 (en) 2018-11-20 2021-09-29 Abbvie Inc. Methods for treating acute hcv
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물
CN111688355B (zh) 2019-03-15 2022-04-12 精工爱普生株式会社 液体吸收体、液体吸收器以及液体喷出装置
MX2021012320A (es) * 2019-04-08 2022-01-18 Abbvie Inc Composiciones farmaceuticas solidas para el tratamiento del hcv.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
JP5857053B2 (ja) * 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来hcvセリンプロテアーゼ阻害剤
US8330139B2 (en) 2011-03-25 2012-12-11 Micron Technology, Inc. Multi-level memory cell
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
LT2968301T (lt) 2013-03-14 2017-05-25 Abbvie Inc. Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui

Also Published As

Publication number Publication date
MX2015012538A (es) 2016-02-10
HUE052113T2 (hu) 2021-04-28
CA2901810C (en) 2019-01-08
SI3213750T1 (sl) 2020-11-30
JP2019048868A (ja) 2019-03-28
BR112015023017A2 (pt) 2017-07-18
NZ719137A (en) 2017-11-24
EP3213750A1 (en) 2017-09-06
ES2624980T3 (es) 2017-07-18
WO2014152514A1 (en) 2014-09-25
IL240419B (en) 2019-03-31
PT3213750T (pt) 2020-10-19
SG11201507364SA (en) 2015-10-29
CN105073113B (zh) 2018-01-02
HUE033010T2 (en) 2017-11-28
DK2968301T3 (da) 2017-07-24
ES2824473T3 (es) 2021-05-12
LT2968301T (lt) 2017-05-25
TW201511759A (zh) 2015-04-01
EA201991174A1 (ru) 2020-01-31
EA033257B1 (ru) 2019-09-30
CA2901810A1 (en) 2014-09-25
EA201591702A1 (ru) 2016-09-30
RS60881B1 (sr) 2020-11-30
NZ631155A (en) 2016-05-27
CY1123387T1 (el) 2021-12-31
IL240419A0 (en) 2015-09-24
TWI686196B (zh) 2020-03-01
AU2014239563B2 (en) 2016-05-05
TW201834656A (zh) 2018-10-01
EP2968301A1 (en) 2016-01-20
EP3213750B1 (en) 2020-08-12
HRP20171036T1 (hr) 2017-10-06
JP6441303B2 (ja) 2018-12-19
EP2968301B1 (en) 2017-04-19
MX362616B (es) 2019-01-28
JP2016513695A (ja) 2016-05-16
AU2016202823B2 (en) 2017-11-23
TWI642436B (zh) 2018-12-01
CN108159393A (zh) 2018-06-15
PL2968301T3 (pl) 2017-09-29
KR20150129032A (ko) 2015-11-18
JP2021130720A (ja) 2021-09-09
SI2968301T1 (sl) 2017-07-31
HK1223817A1 (zh) 2017-08-11
HRP20201575T1 (hr) 2020-12-11
MX2020005054A (es) 2020-08-20
SG10201708306WA (en) 2017-11-29
AU2016202823A1 (en) 2016-05-19
US20140275099A1 (en) 2014-09-18
LT3213750T (lt) 2020-10-26
PL3213750T3 (pl) 2020-12-14
CN105073113A (zh) 2015-11-18
AU2014239563A1 (en) 2015-08-27
EP3766495A1 (en) 2021-01-20
HK1244668A1 (zh) 2018-08-17
JP2020037589A (ja) 2020-03-12
PT2968301T (pt) 2017-07-17
JP6621902B2 (ja) 2019-12-18
KR102210935B1 (ko) 2021-02-02
KR20210013344A (ko) 2021-02-03
BR112015023017B1 (pt) 2022-08-30
RS56202B1 (sr) 2017-11-30
CY1119025T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
DK3213750T3 (da) Kombination af to antivirale midler til behandling af hepatitis c
DK3121164T3 (da) Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK2950786T3 (da) Kombinationsformulering af to antivirale forbindelser
DK2961388T3 (da) Kombinationer af lægemidler
DK2958900T3 (da) 2-aminopyrimidinderivater til behandling af virusinfektioner
DK2968208T3 (da) Behandling af kataplexi
DK3057983T3 (da) Glucagon-analoger
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3023100T3 (da) Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
DK3351047T3 (da) Direkte tilgang-procedure til reduktion af latens
BR302013004540S1 (pt) Configuração aplicada em jóias
BR302013004506S1 (pt) Configuração aplicada em jóias
BR302013004355S1 (pt) Configuração aplicada em jóias
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
BR302013005134S1 (pt) Configuração aplicada em alça de cateter
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
DK3003366T3 (da) På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider
DK3360869T3 (da) Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.
DK3024519T3 (da) Destruktion af hypodermiske kanyler
DK3021911T3 (da) Anordning til indgivelse af lægemidler